Oxford Biomedica plc (LSE:OXB) entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for ?15 million on December 4, 2023. Completion of the transaction is currently expected to take place in the first quarter of 2024 subject to the satisfaction and waiver of outstanding conditions, including obtaining the necessary regulatory approvals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
228.5 GBX | +3.86% | +12.56% | +3.86% |
Apr. 18 | Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT | MT |
Apr. 18 | HSBC likes Haleon, cuts Flutter to 'hold' | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.86% | 285M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford Biomedica plc entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for ?15 million.